{"id":"NCT01114529","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients","officialTitle":"A 24-month, Multi-center, Open-label, Randomized, Controlled Trial to Investigate Efficacy, Safety and Evolution of Cardiovascular Parameters in de Novo Renal Transplant Recipients After Early Calcineurin Inhibitor to Everolimus Conversion","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-08-09","primaryCompletion":"2014-10-30","completion":"2014-10-30","firstPosted":"2010-05-03","resultsPosted":"2017-05-30","lastUpdate":"2017-05-30"},"enrollment":828,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Kidney Transplantation"],"interventions":[{"type":"DRUG","name":"Everolimus","otherNames":["Certican, Zortress, RAD001"]},{"type":"DRUG","name":"Prograf or Neoral","otherNames":["Tacrolimus or Cyclosporine"]}],"arms":[{"label":"Everolimus","type":"EXPERIMENTAL"},{"label":"Calcineurin inhibitor, Prograf or Neoral","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to determine whether an early Calcineurin Inhibitor (CNI) to everolimus conversion at 10-14 weeks post transplantation improves renal allograft function without compromising efficacy compared to standard CNI treatment in de novo renal allograft recipients. In addition, the study was designed to evaluate the impact of a CNI-free regimen on evolution of cardiovascular parameters in de novo renal allograft recipients","primaryOutcome":{"measure":"Estimated Glomerular Filtration Rate (eGFR)","timeFrame":"Month 12","effectByArm":[{"arm":"Everolimus","deltaMin":64.1,"sd":22.31},{"arm":"Standard CNI (Tac)","deltaMin":61.5,"sd":19.86},{"arm":"Standard CNI (CsA)","deltaMin":58.4,"sd":19.62}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":12},"locations":{"siteCount":77,"countries":["Argentina","Australia","Austria","Belgium","Estonia","France","Germany","Greece","India","Italy","Latvia","Lithuania","Mexico","Netherlands","Norway","Portugal","Romania","Russia","Spain","Thailand","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":[],"seeAlso":["https://doi.org/10.1111/ajt.13898"]},"adverseEventsSummary":{"seriousAny":{"events":188,"n":346},"commonTop":["Diarrhoea","Urinary tract infection","Leukopenia","Oedema peripheral","Pyrexia"]}}